Trials / Completed
CompletedNCT00677352
A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
A Randomized, Double-Blind, Multicenter Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 321 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of sertraline compared to paroxetine in patients with panic disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sertraline | dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks |
| DRUG | Paroxetine | dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2010-01-01
- Completion
- 2010-02-01
- First posted
- 2008-05-14
- Last updated
- 2021-01-27
- Results posted
- 2011-05-06
Locations
22 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00677352. Inclusion in this directory is not an endorsement.